Indication
Secondary Hyperparathyroidism Due to Renal Causes
1 clinical trial
3 products
Clinical trial
An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D InsufficiencyStatus: Completed, Estimated PCD: 2020-04-24
Product
CalcifediolProduct
CholecalciferolProduct
Paricalcitol